Selections from The Scientist’s reading list:
- As more and more states legalize medical marijuana, the National Institute on Drug Abuse (NIDA)—which, through a contract with growers at the University of Mississippi in Oxford, supplies all marijuana used for research purposes in the U.S.—is “working to expand the amount and variety of the drug available for study,” Nature reported this week (March 17). According to Nature, however, “the agency’s most potent strains still fall short of the most powerful street pot.”
- 23andMe Therapeutics “won’t change drug discovery,” according to a Bio-IT World column published this week (March 17), noting the firm’s central role as a consumer genetics company. “As a side business alongside 23andMe’s genetic health tests, however, a drug unit is just one more part of the ongoing experiment to show that some knowledge of value...
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!